Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ninlaro + Chemotherapy in Older Adults with ALL
NCT02228772Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose of MLN 9708 at 2 years. Started Dec 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02228772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228772.